Riverwater Partners LLC Has $3.18 Million Stock Holdings in Haemonetics Corporation (NYSE:HAE)

Riverwater Partners LLC lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,014 shares of the medical instruments supplier’s stock after selling 365 shares during the quarter. Haemonetics comprises approximately 1.6% of Riverwater Partners LLC’s portfolio, making the stock its 9th biggest position. Riverwater Partners LLC owned 0.10% of Haemonetics worth $3,178,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Arizona State Retirement System lifted its holdings in shares of Haemonetics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock valued at $1,160,000 after purchasing an additional 181 shares during the last quarter. CWC Advisors LLC. grew its stake in shares of Haemonetics by 7.4% in the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier’s stock worth $241,000 after acquiring an additional 212 shares during the last quarter. Vise Technologies Inc. increased its holdings in shares of Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock valued at $221,000 after acquiring an additional 225 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 244 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Up 1.4%

Shares of Haemonetics stock opened at $69.99 on Friday. Haemonetics Corporation has a twelve month low of $55.30 and a twelve month high of $94.99. The company’s 50 day moving average is $66.00 and its 200 day moving average is $68.68. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The company has a market cap of $3.36 billion, a price-to-earnings ratio of 21.15, a price-to-earnings-growth ratio of 1.13 and a beta of 0.36.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analysts’ expectations of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. Haemonetics’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.90 EPS. Research analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of several recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. Needham & Company LLC dropped their target price on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.